Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Ocular Therapeutix's ebitda for the twelve months ending Jun 30, 2026 was -$308.46M. For fiscal 2025 it was -$265.69M. The highest annual figure on record is -$12.50M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$265.69M | – |
| FY2024 | Dec 31, 2024 | -$168.00M | – |
| FY2023 | Dec 31, 2023 | -$79.40M | – |
| FY2022 | Dec 31, 2022 | -$76.55M | – |
| FY2021 | Dec 31, 2021 | -$75.62M | – |
| FY2020 | Dec 31, 2020 | -$60.07M | – |
| FY2019 | Dec 31, 2019 | -$83.27M | – |
| FY2018 | Dec 31, 2018 | -$56.83M | – |
| FY2017 | Dec 31, 2017 | -$60.30M | – |
| FY2016 | Dec 31, 2016 | -$42.45M | – |
| FY2015 | Dec 31, 2015 | -$37.44M | – |
| FY2014 | Dec 31, 2014 | -$26.55M | – |
| FY2013 | Dec 31, 2013 | -$12.50M | – |
| FY2012 | Dec 31, 2012 | -$13.27M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$80.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$92.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$68.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$67.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$66.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$62.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$49.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$45.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.63M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.70M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.09M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.04M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.28M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.62M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.68M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.18M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.48M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.00M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.07M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.70M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.00M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.89M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.19M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.71M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.99M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.41M | – |
| Q4 FY2016 | Dec 31, 2016 | -$12.22M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.02M | – |
See a number that looks wrong?